1 Effects of Hormone Therapy on survival, cancer, cardiovascular and dementia risks in 7 million 2 menopausal women over age 65: a retrospective observational study 3 Seo H. Baik¹, Fitsum Baye, ¹ Clement J. McDonald¹ 4 5 ¹ Lister Hill National Center for Biomedical Communications, National Library of 6 7 Medicine, National Institutes of Health, Bethesda, Maryland, U.S.A 8 9 **Abstract** 10 **Background** 11 The long-term influence of menopausal hormone therapy remains unanswered due to the termination of randomized clinical trials and discordant findings from observational studies. 12 **Methods** 13 From 2007-2019 enrollment records of 100% Medicare beneficiaries, we identified 7 million 14 female enrollees aged 65 or more. We identified type, route and strength of estrogen based on 15 16 their prescription drug utilization records. Using vital status record and encounter records, we 17 defined the first onset of thirteen patient outcomes; all-cause mortality; 5 cancers (breast, lung, 18 endometrial, colorectal, ovarian cancers); 6 CV conditions (ischemic heart diseases, heart failure, 19 venous thromboembolism, stroke, atrial fibrillation, acute myocardial infarction); and dementia. 20 Then, we implemented an extended Cox regression analysis to examine the effects of type, route, 21 and strength of estrogens on each of 13 study outcomes. 22 23 **Findings**

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

Effects of Hormone Therapy on survival, cancer, cardiovascular, and dementia risks

Estrogen monotherapy (ET) exhibited a significant, 20% (aHR=0.80; 95% CI 0.78-0.82), relative risk reduction of mortality. The reduction was greater with estradiol (aHR=0.78; 95% CI 0.75-0.80) than conjugated estrogen (aHR=0.86; 95% CI 0.85-0.88), and with vaginal (aHR=0.69; 95% CI 0.65-0.74) than oral (aHR=0.89; 95% CI 0.87-0.90) and transdermal (aHR=0.78; 95% CI 0.75-0.81) preparations. ET also exhibited significant risk *reductions* for all study cancers, breast (aHR=0.82; 95% CI 0.80-0.84), lung (aHR=0.87; 95% CI 0.84-0.90), endometrial (aHR=0.65; 95% CI 0.62-0.69), colorectal (aHR=0.86; 95% CI 0.82-0.90) and ovarian (aHR=0.83; 95% CI 0.79-0.88). ET slightly increased risks of ischemic heart diseases (aHR=1.03; 95% CI 1.01-1.04). However, such risk was not observed with low dose ET (aHR=0.98; 95% CI 0.97-0.99). Both combination therapy (aHR=1.11; 95% CI 1.08-1.14) and progestogen monotherapy (aHR=1.09; 95% CI 1.05-1.13) exhibited a significantly increased risk of breast cancer. Oral HT exhibited a moderately increased risk of dementia. **Conclusions** Among female Medicare beneficiaries aged ≥65, the effect of menopausal hormone therapy varies by type, route, and strength but overall estrogen seemed beneficial.

Introduction

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

In 2002, the Women's Health Initiatives (WHI) trial reported that menopausal estrogen+progestogen therapy (EPT) increased the occurrence of invasive breast cancer, stroke, and coronary heart disease in menopausal women (1) though it reduced fractures. The press dramatically presented the negative outcomes in a manner that some described as misleading (2,3). However, most of these results lost significance when corrected for multiple testing (1), and the second WHI study in 2004 examined the effect of estrogen monotherapy (ET) on these same outcomes and reported a near significant reduction in breast cancer (4), which became a significant 22% reduction in WHI's long-term follow-up of that study (5). However, these positive results got little press attention and did little to reduce the fears about hormone therapy (HT) that had already implanted in the public's mind. The WHI trials only studied one type (conjugated estrogen) and dosage (0.625 mg) and route (oral) of estrogen alone and in combination with a progestin. Many have wondered how different the results would have been with other types, routes, and dosage strengths of such medicines. The U.S. Centers for Medicare and Medicaid Services (CMS) Virtual Research Data Center (VRDC) (6) carries 13 years of prescription claims and 20 years of encounter claims (7,8) as well as vital status for most US women over 65, and thus menopausal. So, VRDC provides HT exposure data as well as outcomes data about death, dementia, cardiovascular (CV), and cancer conditions like those studied by the WHI trials. Furthermore, at least 2-7% of elderly women still use HT after age 65 (9), enough that VRDC data might shed light on the consequences of HT use in older women and is large enough to provide data about the effect of dose size, routes and types of estrogens that the WHI trials could not. We implemented an extended Cox regression analyses (10–12) to assess the association of these factors with death, dementia, CV and cancer outcomes. Here we report the results of these analyses.

Methods

Study population

The CMS provided us access to all records of Medicare Part A (hospital insurance), B (medical insurance), and D (prescription drug insurance), claims data for 100% Part D enrollees. We constrained our study sample to be women who were first entitled in Medicare near age 65 (± 1 month) and during the full years of Part D benefits (i.e., 2007–2019) —a total of 13 years. We only included enrollees with at least 6 months of data –to assure enough follow-up time.

We report usage trends broken down by year, HT type and route, using the number of Part D female enrollees in each year as the denominator. We report descriptive statistics of patients' demographics, socio-economic status, the prevalence of 49 chronic conditions, and the associated crude rates of outcomes.

HT exposures

We classified HT into 6 related drug types, 4 routes and 3 dose strengths, as applicable. The drug types included estradiol (E2) alone, conjugated estrogen (CEE) alone, progestin (P) alone, E2+P combined, CEE+P combined and ethinyl estradiol (EE)+P combined. The routes include oral, transdermal, vaginal and injectable. We developed an average daily estrogen dose based on DailyMed (13) dosing instructions for each of 124 individual HT products (see full details in S1 Table) which accommodated intermittent regimens (e.g., 21 days on and 7 days off). We defined a "standard" dose for estrogen type and route, based on the literature and the distribution of daily estrogen doses as 0.625 mg, 1 mg, and 5 μg, for oral CEE, E2, and EE, respectively and 200 μg and 50 μg for non-oral, CEE and E2, respectively. For each drug type, we categorized this average daily estrogen doses into high, greater than 1.45 times the standard; low, less than 0.45

times the standard; and medium, between the lower end of the high, and the upper end of the low, bounds. We considered each combination of estrogen type, dose strength, and route as separate covariates (22 of them). We considered subjects to be exposed to a study drug if they ever had a prescription for that drug prior to an outcome event.

We only included HT medications with indications for menopausal symptoms and excluded the few indicated for birth control or for vaginal bleeding (injectable CEE). We did include injectable E2 which is indicated for menopausal symptoms (14,15). We did not include Megestrol in our study because of its special cancer uses.

Outcomes

Our goals were to describe the usage of HT in women age ≥65 and determine the influence of such usage on survival, and on the occurrence of WHI-like outcomes: 5 cancers, 6 cardiovascular (CV) conditions, and dementia (1,4). The cancer outcomes included breast, lung, endometrial, colorectal, and ovarian, cancers. The CV outcomes included: ischemic heart diseases (IHD), heart failure (HF), venous thromboembolism (VTE), stroke, atrial fibrillation (AFB), and acute myocardial infarction (AMI). The occurrence and onset date for all but ovarian cancer and VTE were predefined by algorithm in Medicare's Chronic Condition Data Warehouse (CCW) (16). We generated comparable occurrence data by examining ICD-9/10-CM codes for ovarian cancer (183.0 and C56) and VTE (415.1, 451, 453, I26, I80, I82), respectively.

Statistical analysis

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

Effects of Hormone Therapy on survival, cancer, cardiovascular, and dementia risks

We explored the independent effect of each HT drug on the 13 outcomes listed above using separate extended Cox regression analyses. In each regression analysis, we included 22 combinations of HT drug type, routes, and dose ranges as covariates. As adjustments for patients' characteristics, we also included race, degree of low-income-subsidy (LIS) (a surrogate for income (17)), rural residence indicator, calendar year of Medicare Part D enrollment (to adjust for secular trends), and the 47 CCW chronic conditions (16) with >1% prevalence, to adjust for overall medical burden. We treated all covariates except race as time-varying to avoid the risk of an immortal time bias and, protect against violations of proportional hazard assumption (10–12). When a cancer, or CV condition, or dementia was the outcome, we excluded all other cancer, CV conditions or dementia conditions, as covariates respectively. Subjects became eligible for the study at the time of their Medicare entitlement, but prescription records were unavailable until their Part D enrollment. Many enrollees in our study also moved from Medicare Fee-For-Service (FFS) to a capitated plan (Medicare Advantage or MA) or disenrolled from Medicare. We had to censor them when that happened because we lost access to their encounter records and associated diagnose. We followed these subjects from their entry to Part D (while accounting for left truncation (18)) until they 1) experienced an outcome of interest, 2) switched to a capitated plan, 3) disenrolled from Medicare or 4) reached 12/31/2019 (the end of our data availability), whichever came first. In order to 1) mitigate selection bias toward HT use and to 2) correct for potential bias from informative censoring, we developed 2 time-varying propensity scores (PSs) using logistic regressions (19–21). The first was for the likelihood of taking HT and the second for the likelihood of switching from Medicare FFS to a capitated plan or disenrolling from Medicare altogether and thus dropping out of the study. Both PSs were conditional probabilities based on patient's characteristics (demographics, socioeconomics, and presence of the 47 chronic conditions) and were iteratively estimated every 6 months among the patients who remained in follow-up considering all covariate values in a given 6-month cycle

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

Effects of Hormone Therapy on survival, cancer, cardiovascular, and dementia risks

(21). We ran all Cox regression analyses with these time-varying PSs as additional adjustments (22,23).Secondary analysis In this study, enrollees who moved from Medicare FFS to a capitated plan or disenrolled from Medicare had to be censored. Because such censoring could be *informative* and result in censoring bias (24), we included a PS of such drop-outs as an extra covariate in our primary analysis. In addition to that, we performed an intention-to-treat (ITT) analysis (25) to assess the possibility that censoring bias accounted for the difference in mortality risk associated with HT use from our primary analysis. In this secondary analysis, we included all female beneficiaries who were still on FFS at one year post Part D enrollment and followed them until death or the end of the study (12/31/2019) while ignoring dropouts after one year. The covariates in this secondary analysis include our study drugs, and all of the other covariates used in our primary analysis but were time-fixed as of their values at or before the one-year cut-off. In addition, we also include the PS of taking any HT as of the one-year cut-off (i.e., time-fixed). This ITT analysis would result in more accurate estimates of drug efficacy than ones yielded from a perprotocol analysis (26). We report the relative risk for each study drug from this analysis. **Results** Study population and Secular trends From 100% Part D senior female enrollees, more than 7 million satisfied our selection criteria.

From 100% Part D senior female enrollees, more than 7 million satisfied our selection criteria.

The death cohort, our largest, included 7,036,466 individuals, and a modest proportion, 15%, of

them used some type of HT at least once during our study period (Table 1). The disease-specific cohorts were slightly smaller in number but had similar proportions of HT users.

Table 1. Baseline Characteristics

163

164

165

	Any HT	Neither
N	1,082,565	5,953,901
Age at Part D Entry, Median (IQR)	64.0(64.0-65.0)	64.0(64.0-65.0)
Age at The End of Follow-Up, Median (IQR)	71.0(68.0-74.0)	69.0(67.0-72.0)
White	965,436(89.2)	4,791,602(80.5)
Black	34,503(3.2)	465,960(7.8)
Hispanic	36,392(3.4)	350,606(5.9)
Asian	17,075(1.6)	177,022(3.0)
Other	29,159(2.7)	168,711(2.8)
Ever Dual	87,787(8.1)	1,004,457(16.9)
Non-Dual LIS	14,179(1.3)	156,754(2.6)
Non-Dual No LIS	980,599(90.6)	4,792,690(80.5)
Living In Rural Area	289,562(26.7)	1,605,895(27.0)
Hysterectomy	231,611(21.4)	639,809(10.7)
Cataract	718,924(66.4)	2,954,232(49.6)
Chronic Kidney Disease	221,782(20.5)	1,284,284(21.6)
COPD	174,424(16.1)	932,907(15.7)
Diabetes	240,201(22.2)	1,664,431(28.0)
Glaucoma	223,538(20.6)	952,997(16.0)
Hip/Pelvic Fracture	15,723(1.5)	82,706(1.4)
Depression	412,225(38.1)	1,727,657(29.0)
Alzheimer's Disease or Senile Dementia	63,605(5.9)	309,437(5.2)
Osteoporosis	268,653(24.8)	1,135,562(19.1)
Rheumatoid Arthritis/Osteoarthritis	657,040(60.7)	2,638,202(44.3)
Anemia	443,105(40.9)	2,035,431(34.2)
Asthma	167,973(15.5)	667,100(11.2)
Hyperlipidemia	811,559(75.0)	4,016,394(67.5)
Hypertension	721,052(66.6)	3,926,742(66.0)
Hypothyroidism	394,493(36.4)	1,576,154(26.5)
Alcohol Use Disorders	19,208(1.8)	115,692(1.9)
Anxiety Disorders	345,272(31.9)	1,363,862(22.9)
Bipolar Disorder	34,909(3.2)	143,139(2.4)
Major Depressive Affective Disorder	314,194(29.0)	1,290,630(21.7)
Drug Use Disorder	37,411(3.5)	157,354(2.6)
Personality Disorders	27,095(2.5)	93,976(1.6)
Schizophrenia and other Psychotic Disorders	18,016(1.7)	107,525(1.8)
Epilepsy	19,718(1.8)	110,771(1.9)

Cystic Fibrosis and other Metabolic Developmental Disorders	23,581(2.2)	83,419(1.4)
Fibromyalgia, Chronic Pain and Fatigue	439,070(40.6)	1,569,200(26.4)
Viral Hepatitis (General)	10,304(1.0)	62,552(1.1)
Liver Disease Cirrhosis and other Liver Conditions (Excluding Hepatitis)	105,312(9.7)	487,132(8.2)
Leukemias and Lymphomas	19,399(1.8)	92,685(1.6)
Migraine and other Chronic Headache	117,950(10.9)	327,037(5.5)
Mobility Impairments	20,922(1.9)	140,658(2.4)
Obesity	252,541(23.3)	1,634,171(27.4)
Overarching OUD Disorder	30,997(2.9)	105,841(1.8)
Peripheral Vascular Disease	112,913(10.4)	601,917(10.1)
Tobacco Use Disorders	78,084(7.2)	633,390(10.6)
Pressure Ulcers and Chronic Ulcers	35,812(3.3)	221,553(3.7)
Sensory - Deafness and Hearing Impairment	125,001(11.5)	399,956(6.7)

Note. Data are presented as No. (%) of patients unless otherwise noted.

Abbreviations: HT = Hormone Therapy; IQR = Interquartile Range; AMI = Acute Myocardial Infarction; COPD =

Chronic Obstructive Pulmonary Disease.

 Over the 13 years of follow-up (2007-2019), the proportion of senior women taking any HT containing estrogen dropped by half, from 11.4% to 5.8%. E2 tended to replace CEE; EPT plummeted from 1.4% to a minuscule 0.2% (Figure 1a); and vaginal route tended to replace oral route (Figure 1b). Overall, the number of ET users was 8 to 10 times greater than the number of EPT or P alone users, respectively. Among ET users, the predominant route was vagina. Twice as many women were on vaginal and 1/3rd as many on transdermal as on oral preparations. Among EPT users, the most common type of EPT was E2+P, followed by CEE+P and then EE+P (Table 2). All prescriptions of EE+P were a combination of EE and norethindrone and we did not include the 8% of the EE+P preparations indicated for birth control for consistency's sake though that indication made no sense for our senior population.

Figure 1. Trend in the use of Hormone Therapy (HT) by type and route

- (a) Secular Trend in HT use by type
- (b) Secular Trend in HT use by route

Table 2. Number (Percentage) of patients by Route, Type, and Strength in Death Cohort (N = 7,036,466)

	N (%)
Estrogen without Progestin	990,315(14.1)
By type	
CEE	401,499(5.7)
E2	717,785(10.2)
By route	
Oral	314,514(4.5)
Transdermal	104,116(1.5)
Vaginal	668,052(9.5)
Injection	3,398(0.0)
By dose	
Low	334,299(4.8)
Medium	506,088(7.2)
High	390,817(5.6)
Progestin without Estrogen	100,712(1.4)
Estrogen with Progestin	127,174(1.8)
By type	
CEE	52,671(0.7)
E2	77,578(1.1)
EE	9,473(0.1)
By route	
Oral	109,739(1.6)
Transdermal	21,439(0.3)
By dose	
Low	60,804(0.9)
Medium	84,284(1.2)

Starting with Part D enrollment, the median follow-up in death cohort was 4.1 years (total of 33,171,664 person-years); it was longer among any HT users (5.8 years) than no HT users (3.9 years) (Table 3). Overall, 384,376 patients died (5.5% or 12 per 1000 person-years). The death incidence was lower among HT users than no HT users (6 vs 13 per 1000 person-years). We censored 1.5 out of 7 million subjects as they left FFS for MA plans (17.7%) or dis-enrolled from Medicare (4.5%). The rate of censoring for this reason was higher among no HT users, indicating potential bias from informative censoring. The number of subjects and follow-up duration varied

somewhat across disease-specific cohorts because of different end points and censoring rates by outcomes.

197

Table 3. Event/Censoring Points and Rates of Event/Death by Each Study Cohort

					End Points			Rate 10	00 PPY
Outcome		N	Event	Death	Censored at MA entry	Censored at Disenrollment	Censored at 12/31/2019	Event	Death
Doodh	any HT	1,082,565	N/A	39,577(3.7)	150,222(13.9)	35,504(3.3)	857,262(79.2)	N/A	6.08
Death	no HT	5,953,901	N/A	344,799(5.8)	1,092,537(18.3)	280,906(4.7)	4,235,659(71.1)	N/A	12.93
Dunget gamage	any HT	1,052,546	40,022(3.8)	35,485(3.4)	144,121(13.7)	34,040(3.2)	798,878(75.9)	6.49	5.75
Breast cancer	no HT	5,680,297	272,143(4.8)	291,089(5.1)	1,023,231(18.0)	263,599(4.6)	3,830,235(67.4)	11.11	11.88
I una concen	any HT	1,078,052	11,288(1.0)	33,014(3.1)	149,387(13.9)	35,275(3.3)	849,088(78.8)	1.75	5.11
Lung cancer	no HT	5,922,463	81,085(1.4)	287,675(4.9)	1,085,123(18.3)	278,767(4.7)	4,189,813(70.7)	3.07	10.89
Endometrial cancer	any HT	1,077,618	8,994(0.8)	37,998(3.5)	148,967(13.8)	35,210(3.3)	846,449(78.5)	1.39	5.89
Endometrial cancer	no HT	5,923,782	61,594(1.0)	329,064(5.6)	1,082,244(18.3)	278,194(4.7)	4,172,686(70.4)	2.34	12.48
Colomostal compon	any HT	1,075,782	8,403(0.8)	37,411(3.5)	148,792(13.8)	35,128(3.3)	846,048(78.6)	1.30	5.81
Colorectal cancer	no HT	5,917,758	59,779(1.0)	323,121(5.5)	1,080,922(18.3)	277,890(4.7)	4,176,046(70.6)	2.27	12.26
Ovarian cancer	any HT	1,078,089	6,780(0.6)	37,399(3.5)	149,311(13.8)	35,271(3.3)	849,328(78.8)	1.05	5.79
	no HT	5,929,939	37,104(0.6)	326,343(5.5)	1,086,482(18.3)	279,191(4.7)	4,200,819(70.8)	1.40	12.33
IHD	any HT	951,610	166,989(17.5)	18,049(1.9)	116,519(12.2)	28,180(3.0)	621,873(65.3)	33.00	3.57
	no HT	5,443,478	901,630(16.6)	163,325(3.0)	869,673(16.0)	230,529(4.2)	3,278,321(60.2)	41.67	7.55
CHE	any HT	1,044,298	77,330(7.4)	22,746(2.2)	138,138(13.2)	32,860(3.1)	773,224(74.0)	12.82	3.77
CHF	no HT	5,766,670	498,335(8.6)	189,032(3.3)	994,579(17.2)	258,489(4.5)	3,826,235(66.4)	20.25	7.68
VTE	any HT	1,052,177	62,049(5.9)	27,509(2.6)	141,235(13.4)	33,494(3.2)	787,890(74.9)	10.17	4.51
VIE	no HT	5,838,124	344,291(5.9)	243,558(4.2)	1,034,742(17.7)	267,052(4.6)	3,948,481(67.6)	13.64	9.65
Stroke	any HT	1,060,043	54,390(5.1)	30,427(2.9)	142,507(13.4)	33,623(3.2)	799,096(75.4)	8.79	4.92
Stroke	no HT	5,868,084	295,106(5.0)	270,101(4.6)	1,038,692(17.7)	267,162(4.6)	3,997,023(68.1)	11.56	10.58
A ED	any HT	1,053,942	49,421(4.7)	31,236(3.0)	143,595(13.6)	33,993(3.2)	795,697(75.5)	8.01	5.06
AFB	no HT	5,836,153	283,134(4.9)	273,370(4.7)	1,046,200(17.9)	270,068(4.6)	3,963,381(67.9)	11.15	10.76
AMI	any HT	1,078,265	13,649(1.3)	36,361(3.4)	148,722(13.8)	35,178(3.3)	844,355(78.3)	2.12	5.64
AMI	no HT	5,932,105	97,403(1.6)	312,394(5.3)	1,078,808(18.2)	277,336(4.7)	4,166,164(70.2)	3.70	11.85
Domontio	any HT	1,067,719	48,759(4.6)	29,032(2.7)	144,177(13.5)	33,804(3.2)	811,947(76.0)	7.75	4.61
Dementia	no HT	5,893,885	249,421(4.2)	263,399(4.5)	1,052,811(17.9)	269,694(4.6)	4,058,560(68.9)	9.63	10.17

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

Notes: Data are presented as No. (%) of patients unless otherwise noted. Abbreviations: HT = Hormone Therapy; PPY = Person-Per-Year; MA = Medicare Advantage; IHD = Ischemic Heart Disease; HF = Heart Failure; VTE = Venous thromboembolism; AFB = Atrial Fibrillation; AMI = Acute Myocardial Infarction. Medicaid eligibility for special supplements was our proxy for income level. Accordingly, there were three income groups; dual (15%) with incomes below 135% of the Federal Poverty Line (FPL); non-dual LIS (2.4%) between 135% and 150% FPL; and non-dual no LIS (82.0%) above 150% FLP (27). The proportions of non-Hispanic White and rural resident were 81.8% and 26.9% respectively. Among the chronic conditions, hyperlipidemia (68.6%), hypertension (66.1%), and cataract (52.2%), were the most common (Table 1). Because we had no claims data about hysterectomies performed before age 65, hysterectomy data was only available for 12.4% of our cohort and most of it came from the ICD diagnosis codes for "acquired absence of uterus/cervix" (S2 Table). Primary Analyses In Tables 4 and 5, we present the marginal relative risk of 13 study outcomes associated with the use of each HT after controlling for all time-varying and time-fixed covariates including the use of any other HT beyond the index HT, namely adjusted hazard ratio (aHR). We report aHR as the percent of risk above (increased) or below (decreased) one by an amount of 100 x (aHR-1)%. We present marginal aHR by overall use of ET, EPT and Progestin to highlight average differences by type, route, and dose level. We also present aHR for each of 22 combinations of type, route, and dose level in Tables 6 and 7, where oral medium dose CEE and CEE+P indicate comparable drugs studied in the WHI trials.

Table 4. Marginal effects of HT regimens on all-cause mortality and cancer outcomes.

Marginal HT	(a) Death	(b) Death; ITT	(c) Breast	(d) Lung	(e) Endometrial	(f) Colorectal	(g) Ovarian
Estrogen without Progestin	0.80(0.78,0.82)\$	0.73(0.71,0.75)\$	0.82(0.80,0.84)*	0.87(0.84,0.90)\$	0.65(0.62,0.69)\$	0.86(0.82,0.90)\$	0.83(0.79,0.88)*
By type							
CEE	0.86(0.85,0.88)\$	0.85(0.84,0.87)\$	0.74(0.72,0.76)\$	0.91(0.88,0.94)\$	0.66(0.62,0.70)\$	0.89(0.85,0.93)\$	0.80(0.75,0.85)\$
E2	0.78(0.75,0.80)\$	0.68(0.66,0.71)*	0.85(0.83,0.88)\$	0.86(0.81,0.90)*	0.64(0.60,0.69)\$	0.84(0.79,0.90)*	0.85(0.79,0.91)\$
By route							-
Oral	0.89(0.87,0.90)\$	0.88(0.87,0.90)\$	0.75(0.73,0.76)*	0.92(0.89,0.94)*	0.59(0.56,0.62)*	0.86(0.83,0.90)\$	0.79(0.75,0.83)*
Transdermal	0.78(0.75,0.81)\$	0.66(0.63,0.69)*	0.83(0.80,0.85)\$	0.84(0.79,0.89)*	0.65(0.61,0.70)\$	0.83(0.77,0.89)*	0.83(0.77,0.90)\$
Vaginal	0.69(0.65,0.74)*	0.54(0.49,0.58)*	0.94(0.90,0.98)	0.79(0.72,0.88)*	0.82(0.74,0.91)\$	0.81(0.73,0.91)*	0.97(0.87,1.08)
Injection	0.84(0.74, 0.95)	1.08(0.94,1.24)	0.81(0.68, 0.97)	1.01(0.80,1.26)	0.47(0.29, 0.76)	1.11(0.82,1.52)	0.63(0.38,1.05)
By dose							
Low	0.79(0.77,0.81)\$	0.66(0.64,0.68)\$	0.86(0.85,0.88)*	0.84(0.81,0.88)\$	0.72(0.68,0.75)*	0.82(0.78,0.86)\$	0.86(0.81,0.90)\$
Medium	0.76(0.72,0.80)\$	0.65(0.60,0.69)\$	0.82(0.79,0.85)\$	0.84(0.77,0.91)\$	0.68(0.63,0.75)\$	0.83(0.76,0.92)*	$0.86(0.79, 0.94) \downarrow$
High	0.84(0.82,0.87)\$	0.89(0.86,0.93)\$	0.78(0.75,0.82)\$	0.92(0.87, 0.98)	0.57(0.51,0.64)*	0.91(0.85,0.99)↓	0.78(0.70,0.88)\$
Progestin without Estrogen	0.98(0.94,1.01)	0.94(0.90,0.99)↓	1.09(1.05,1.13)*	0.91(0.84,0.98)↓	3.32(3.15,3.49)*	1.05(0.97,1.14)	1.67(1.55,1.81)*
Estrogen with Progestin	0.88(0.85,0.91)*	0.78(0.75,0.81)\$	1.11(1.08,1.14)*	0.94(0.88,0.99)↓	0.65(0.59,0.71)*	0.92(0.86,0.98)↓	1.01(0.94,1.09)
By type							
CEE	0.93(0.90,0.97)\$	0.83(0.80,0.87)\$	1.10(1.07,1.14)	0.96(0.90,1.02)	0.72(0.66,0.78)\$	0.91(0.84,0.98)↓	1.09(1.01,1.19)↑
E2	0.87(0.84,0.91)\$	0.78(0.74,0.82)\$	1.12(1.08,1.16)	0.89(0.82,0.96)↓	0.72(0.67,0.78)\$	0.95(0.87,1.03)	0.99(0.91,1.08)
EE	0.83(0.76,0.92)\$	0.74(0.66,0.82)*	1.11(1.03,1.19)	0.99(0.84,1.16)	0.49(0.37,0.65)\$	0.88(0.72,1.08)	0.97(0.79,1.20)
By route							
Oral	0.89(0.86,0.92)\$	0.79(0.76,0.82)*	1.11(1.08,1.14)*	0.96(0.90,1.02)	0.62(0.57,0.69)\$	0.90(0.83,0.97)↓	1.00(0.92,1.08)
Transdermal	0.83(0.75,0.91)\$	0.74(0.67,0.82)\$	1.10(1.03,1.18)	0.82(0.70,0.97)	0.80(0.70,0.92)	1.04(0.89,1.23)	1.11(0.95,1.31)
By dose							
Low	0.88(0.82,0.94)\$	0.74(0.69,0.79)\$	1.06(1.01,1.11)↑	0.96(0.86,1.07)	0.67(0.57,0.78)*	0.85(0.74,0.97)↓	1.07(0.93,1.22)
Standard	0.88(0.84,0.92)\$	0.82(0.78,0.86)\$	1.15(1.11,1.19)	0.92(0.85, 0.99)	0.63(0.57,0.71)*	0.97(0.89,1.06)	0.98(0.89,1.07)

224

225

227	Notes: Data are presented as adjusted Hazard Ratio (aHR) and its 95% Confidence Interval (CI).
228	\uparrow = very significantly high with P-value < 0.001, \uparrow = significantly high with 0.001 \leq P-value < 0.05
229	\neq very significantly low with P-value < 0.001, \downarrow = significantly low with 0.001 \leq P-value < 0.05
230	
231	
232	
233	
234	
235	
236	
237	
238	
239	
240	
241	
242	
243	
244	
245	
246	
247	
248	

Table 5. Marginal effects of HT regimens on CV outcomes and dementia

Marginal HT	(a) IHD	(b) CHF	(c) VTE	(d) Stroke	(e) AFM	(f) AMI	(g) Dementia
Estrogen without Progestin	1.03(1.02,1.04)	0.95(0.94,0.96)\$	0.96(0.95,0.98)\$	1.01(1.00,1.03)	0.95(0.93,0.97)*	0.89(0.86,0.93)\$	0.98(0.96,0.99)↓
By type							
CEE	1.04(1.03,1.05)	0.99(0.98,1.00)	0.97(0.96,0.99)↓	1.06(1.04,1.08)*	0.99(0.98,1.01)	0.93(0.90,0.96)\$	1.01(0.99,1.03)
E2	1.03(1.02,1.05)*	0.93(0.92,0.95)*	0.96(0.94,0.98)\$	1.00(0.98,1.02)	0.93(0.91,0.95)*	0.88(0.84,0.92)\$	0.96(0.94, 0.99)
By route							_
Oral	1.03(1.02,1.04)	1.01(0.99,1.02)	0.97(0.96,0.99)\$	1.06(1.05,1.08)	0.99(0.98,1.01)	0.93(0.91,0.96)\$	1.01(1.00,1.03)↑
Transdermal	1.00(0.98,1.01)	0.89(0.87,0.91)*	0.93(0.91,0.95)*	0.94(0.92,0.97)*	0.92(0.89,0.94)*	0.87(0.82,0.92)*	0.91(0.89,0.94)*
Vaginal	1.03(1.00,1.05)↑	0.87(0.84,0.90)\$	0.96(0.92, 0.99)	0.98(0.94,1.02)	0.93(0.89, 0.97)	0.83(0.75,0.91)*	0.94(0.90, 0.99)
Injection	1.19(1.10,1.28)*	1.17(1.06,1.29)	1.02(0.91,1.15)	1.12(0.99,1.27)	0.86(0.74, 0.99)	1.05(0.85,1.31)	1.08(0.95,1.22)
By dose							_
Low	0.98(0.97,0.99)*	0.86(0.85,0.88)*	0.92(0.91,0.94)*	0.94(0.92,0.95)*	0.93(0.91,0.95)*	0.83(0.80,0.86)*	0.91(0.89,0.93)*
Medium	1.02(1.00,1.04)↑	0.93(0.90,0.96)*	0.96(0.93, 0.99)	1.00(0.97,1.04)	0.95(0.92,0.99)	0.88(0.82, 0.95)	0.98(0.94,1.01)
High	1.09(1.07,1.11)*	1.05(1.03,1.08)*	1.00(0.97,1.03)	1.09(1.06,1.13)*	0.96(0.93,0.99)↓	0.96(0.91,1.01)	1.03(1.00,1.06)↑
Progestin without Estrogen	1.03(1.01,1.05)↑	1.04(1.01,1.07)	1.03(1.00,1.06)	0.99(0.95,1.02)	1.04(1.01,1.08)	0.86(0.81,0.93)*	0.99(0.95,1.03)
Estrogen with Progestin	0.96(0.94,0.97)*	0.89(0.87,0.91)*	0.96(0.93,0.98)↓	0.93(0.90,0.95)*	0.92(0.89,0.95)*	0.93(0.87, 0.98)	1.03(1.00,1.06)↑
By type							
CEE	0.95(0.93,0.96)\$	0.91(0.89,0.94)*	0.94(0.91,0.97)*	0.93(0.90,0.96)\$	0.92(0.89,0.95)*	0.95(0.90,1.01)	1.02(0.98,1.05)
E2	0.98(0.96,1.00)	0.89(0.86,0.92)*	0.96(0.93, 0.99)	0.93(0.90,0.96)\$	0.92(0.89,0.96)*	0.95(0.88,1.02)	1.04(1.00,1.07)
EE	0.93(0.89, 0.97)	0.87(0.81,0.94)*	0.97(0.91,1.05)	0.92(0.85,1.00)	0.91(0.84,0.99)↓	0.87(0.73,1.03)	1.04(0.95,1.12)
By route							_
Oral	0.94(0.93,0.96)*	0.89(0.87,0.91)*	0.96(0.93, 0.98)	0.93(0.90,0.96)\$	0.91(0.88,0.94)*	0.93(0.87, 0.99)	$1.03(1.00,1.07)\uparrow$
Transdermal	1.03(1.00,1.07)	0.91(0.85, 0.97)	0.96(0.90,1.02)	0.93(0.87,1.00)	0.98(0.91,1.05)	0.90(0.77,1.05)	1.01(0.94,1.09)
By dose							
Low	0.94(0.91,0.97)*	0.87(0.83,0.92)*	0.95(0.90,1.00)↓	0.90(0.85,0.96)*	0.89(0.84,0.95)*	0.88(0.78, 0.98)	0.97(0.91,1.02)
Standard	0.97(0.95,0.99)↓	0.91(0.88,0.93)*	0.96(0.93,0.99)↓	0.95(0.91,0.98)	0.94(0.90,0.97)	0.97(0.90,1.04)	1.08(1.04,1.12)*

249

250

252	Notes: Data are presented as adjusted Hazard Ratio (aHR) and its 95% Confidence Interval (CI).
253 254	Abbreviations: IHD = ischemic heart diseases; HF = heart failure; VTE = venous thromboembolism; AFB = atrial fibrillation; AMI = acute myocardial infarction.
255	\uparrow = very significantly high with P-value < 0.001 , \uparrow = significantly high with $0.001 \le P$ -value < 0.05
256	\neq very significantly low with P-value < 0.001 , \downarrow = significantly low with $0.001 \le P$ -value < 0.05
257	
258	
259	
260	
261	
262	
263	
264	
265	
266	
267	
268	
269	
270	
271	
272	
273	

Table 6. Hazard ratios of 22 HT regimens on all-cause mortality and cancer outcomes

275

276

277

278

279

HT	(a) Death	(b) Death; ITT	(c) Breast	(d) Lung	(e) Endometrial	(f) Colorectal	(g) Ovarian
Oral CEE - Low Dose	0.84(0.81,0.87)*	0.73(0.70,0.76)*	0.77(0.74,0.80)\$	0.90(0.84,0.97)↓	0.62(0.56,0.69)*	0.85(0.78,0.93)*	0.78(0.70,0.87)*
Oral CEE - Medium Dose	0.91(0.89,0.94)*	0.91(0.89,0.94)*	0.71(0.68,0.73)\$	0.90(0.86,0.95)\$	0.69(0.64,0.75)\$	0.86(0.80,0.92)*	0.76(0.69,0.83)*
Oral CEE - High Dose	0.95(0.90,1.00)	1.17(1.11,1.23)	0.66(0.60,0.72)*	1.03(0.93,1.15)	0.48(0.39,0.60)\$	0.96(0.83,1.11)	0.73(0.60,0.91)
Oral E2 - Low Dose	0.85(0.82,0.88)*	0.76(0.73,0.79)*	0.78(0.75, 0.81)\$	0.85(0.80,0.91)\$	0.62(0.56,0.68)\$	0.81(0.75,0.88)*	0.82(0.75,0.90)\$
Oral E2 - Medium Dose	0.85(0.83,0.88)*	0.81(0.78,0.84)*	0.78(0.76, 0.81)\$	0.88(0.83,0.93)\$	0.55(0.51,0.60)\$	0.87(0.81,0.93)*	0.82(0.75,0.90)*
Oral E2 - High Dose	0.92(0.87, 0.98)	0.98(0.92,1.04)	0.79(0.74,0.84)*	0.94(0.85,1.04)	0.58(0.49,0.68)*	0.85(0.74, 0.98)	0.81(0.69, 0.96)
Transdermal E2 - Low Dose	0.78(0.72,0.85)*	0.61(0.56,0.67)*	0.90(0.85, 0.96)	0.80(0.70, 0.92)	0.75(0.65,0.85)\$	0.83(0.72,0.96)↓	0.78(0.67, 0.91)
Transdermal E2 - Medium Dose	0.73(0.69,0.76)\$	0.63(0.60,0.66)\$	0.80(0.77, 0.83)\$	0.85(0.78,0.92)*	0.72(0.65,0.80)\$	0.84(0.76,0.92)*	0.90(0.81,1.00)
Transdermal E2 - High Dose	0.83(0.77,0.88)*	0.74(0.69,0.80)*	0.78(0.73,0.83)\$	0.87(0.77, 0.98)	0.51(0.44,0.60)\$	0.81(0.71, 0.93)	0.82(0.71, 0.96)
Vaginal CEE - Medium Dose	0.76(0.75,0.78)*	0.67(0.66,0.69)\$	0.84(0.83,0.86)\$	0.79(0.77,0.83)\$	0.92(0.88,0.96)\$	0.90(0.86,0.94)*	0.93(0.89, 0.98)
Vaginal E2 - Low Dose	0.71(0.69,0.73)*	0.54(0.52,0.56)\$	$1.03(1.00,1.05)\uparrow$	0.81(0.77,0.85)*	0.92(0.87, 0.97)	0.78(0.73,0.83)*	1.08(1.02,1.15)
Vaginal E2 - Medium Dose	0.60(0.46,0.77)*	0.36(0.26,0.50)*	1.00(0.85,1.17)	0.79(0.53,1.17)	0.59(0.39, 0.90)	0.72(0.46,1.14)	0.92(0.60,1.40)
Vaginal E2 - High Dose	0.71(0.69,0.72)*	0.63(0.61,0.65)*	0.89(0.87,0.91)\$	0.79(0.76,0.82)\$	0.90(0.86,0.94)\$	0.87(0.83,0.91)*	0.96(0.91,1.01)
Injection E2 - High Dose	0.84(0.74, 0.95)	1.08(0.94,1.24)	0.81(0.68, 0.97)	1.01(0.80,1.26)	0.47(0.29, 0.76)	1.11(0.82,1.52)	0.63(0.38,1.05)
Oral CEE+P - Low Dose	0.90(0.85,0.95)\$	0.75(0.71, 0.80)\$	1.03(0.98,1.08)	0.90(0.81, 0.99)	0.72(0.64,0.82)\$	0.86(0.76, 0.97)	1.13(1.00,1.28)
Oral CEE+P- Medium Dose	0.96(0.92,1.01)	0.93(0.88, 0.97)	1.19(1.13,1.24)	1.02(0.93,1.12)	0.72(0.64,0.81)\$	0.95(0.85,1.07)	1.06(0.93,1.20)
Oral E2+P - Low Dose	0.87(0.80,0.94)\$	0.77(0.70,0.84)\$	$1.07(1.01,1.13)\uparrow$	1.01(0.89,1.15)	0.64(0.56,0.74)\$	0.87(0.74,1.01)	0.97(0.83,1.13)
Oral E2+P - Medium Dose	0.93(0.87, 0.99)	0.83(0.78,0.89)\$	1.19(1.13,1.25)	0.85(0.75, 0.96)	0.73(0.64,0.83)\$	0.94(0.82,1.07)	0.91(0.79,1.05)
Oral EE+P - Low Dose	0.87(0.73,1.04)	0.69(0.57,0.84)\$	1.09(0.95,1.24)	0.98(0.73,1.31)	0.64(0.41, 0.99)	0.82(0.57,1.18)	1.12(0.78,1.60)
Oral EE+P - Medium Dose	$0.80 (0.70,\!0.91) \!\!\downarrow$	0.78(0.69,0.89)\$	1.13(1.02,1.24)	1.00(0.81,1.24)	0.38(0.26,0.57)\$	0.95(0.74,1.23)	0.84(0.62,1.15)
Transdermal E2+P - Medium Dose	0.83(0.75,0.91)\$	0.74(0.67,0.82)\$	1.10(1.03,1.18)	0.82(0.70,0.97)	0.80(0.70,0.92)	1.04(0.89,1.23)	1.11(0.95,1.31)
Progestin monotherapy	0.98(0.94,1.01)	0.94(0.90,0.99)↓	1.09(1.05,1.13)	0.91(0.84,0.98)↓	3.32(3.15,3.49)	1.05(0.97,1.14)	1.67(1.55,1.81)

Notes: Data are presented as adjusted Hazard Ratio (aHR) and its 95% Confidence Interval (CI).

 \uparrow = very significantly high with P-value < 0.001, \uparrow = significantly high with 0.001 \leq P-value < 0.05

 ψ = very significantly low with P-value < 0.001, ψ = significantly low with 0.001 ≤ P-value < 0.05

Table 7. Hazard ratios of 22 HT regimens on CV outcomes and dementia

282

283

284

нт	(a) IHD	(b) CHF	(c) VTE	(d) Stroke	(e) AFM	(f) AMI	(g) Dementia
Oral CEE - Low Dose	0.97(0.95,0.99)↓	0.89(0.87,0.92)*	0.92(0.89,0.95)*	0.97(0.94,1.00)	0.93(0.90,0.97)*	0.90(0.84,0.96)↓	0.95(0.91,0.98)↓
Oral CEE - Medium Dose	1.04(1.02,1.05)	1.02(1.00,1.04)	0.98(0.95,1.00)	1.07(1.04,1.10)*	1.01(0.98,1.03)	0.96(0.91,1.01)	1.00(0.97,1.02)
Oral CEE - High Dose	1.13(1.10,1.17)	1.19(1.14,1.24)*	1.03(0.98,1.09)	1.25(1.19,1.32)*	1.12(1.06,1.18)*	1.00(0.91,1.11)	1.13(1.07,1.19)*
Oral E2 - Low Dose	0.98(0.96,1.00)	0.91(0.89,0.93)*	0.91(0.89,0.94)*	0.95(0.92,0.98)↓	0.94(0.91,0.97)*	0.88(0.83,0.93)*	0.94(0.91, 0.98)
Oral E2 - Medium Dose	1.01(1.00,1.03)	0.98(0.96,1.00)	0.98(0.95,1.00)	1.05(1.02,1.08)	$0.96(0.93, 0.98) \downarrow$	0.90(0.85,0.95)*	1.02(0.99,1.05)
Oral E2 - High Dose	1.07(1.04,1.10)	1.08(1.03,1.12)*	1.03(0.98,1.08)	1.11(1.06,1.17)	1.00(0.95,1.06)	0.95(0.86,1.05)	$1.07(1.01,1.12)\uparrow$
Transdermal E2 - Low Dose	0.98(0.95,1.01)	0.84(0.79,0.88)\$	0.92(0.87, 0.97)	0.90(0.85,0.95)*	0.93(0.87, 0.98)	0.82(0.72,0.93)	0.87(0.82,0.93)*
Transdermal E2 - Medium Dose	1.00(0.98,1.02)	0.88(0.85, 0.91)\$	0.94(0.90,0.97)\$	0.92(0.89,0.96)\$	0.93(0.90,0.97)	0.84(0.77, 0.91)\$	0.94(0.90,0.98)
Transdermal E2 - High Dose	1.02(0.99,1.05)	0.96(0.91,1.00)	0.93(0.89, 0.98)	1.01(0.96,1.07)	0.89(0.84,0.94)\$	0.95(0.85,1.06)	0.94(0.88, 0.99)
Vaginal CEE - Medium Dose	1.02(1.01,1.03)	0.88(0.87, 0.90) *	0.97(0.95,0.98)\$	0.97(0.96,0.99)↓	0.93(0.91,0.94)\$	0.86(0.84,0.89)\$	0.98(0.96, 0.99)
Vaginal E2 - Low Dose	0.99(0.98,1.00)	0.81(0.79,0.83)\$	0.94(0.92,0.96)\$	0.93(0.91,0.95)\$	0.91(0.89,0.94)\$	0.73(0.69,0.77)\$	0.88(0.86,0.90)*
Vaginal E2 - Medium Dose	1.04(0.95,1.14)	0.88(0.76,1.03)	0.94(0.80,1.09)	1.01(0.86,1.20)	0.94(0.79,1.12)	0.86(0.60,1.25)	0.95(0.79,1.14)
Vaginal E2 - High Dose	1.06(1.05,1.08)	0.90(0.89,0.92)\$	0.98(0.96,1.00)	0.98(0.96,1.00)	0.95(0.93,0.96)\$	0.85(0.82,0.89)\$	0.97(0.95,0.98)*
Injection E2 - High Dose	1.19(1.10,1.28)	1.17(1.06,1.29)	1.02(0.91,1.15)	1.12(0.99,1.27)	0.86(0.74, 0.99)	1.05(0.85,1.31)	1.08(0.95,1.22)
Oral CEE+P - Low Dose	0.94(0.91,0.97)\$	0.87(0.84,0.91)\$	0.90(0.86,0.94)\$	0.89(0.84,0.93)\$	0.90(0.85,0.95)\$	0.91(0.82,1.00)	0.98(0.93,1.04)
Oral CEE+P- Medium Dose	0.95(0.93,0.98)\$	0.96(0.92,1.00)	0.98(0.93,1.02)	0.98(0.93,1.02)	0.94(0.90,0.99)	1.00(0.92,1.09)	$1.05(1.00,1.10)\uparrow$
Oral E2+P - Low Dose	0.97(0.94,1.01)	0.89(0.84,0.94)\$	0.95(0.90,1.00)	0.93(0.87, 0.99)	0.90(0.85, 0.96)	1.02(0.90,1.15)	0.97(0.91,1.04)
Oral E2+P - Medium Dose	0.93(0.90,0.96)\$	0.87(0.83,0.92)*	0.97(0.92,1.02)	0.93(0.88, 0.98)	0.89(0.84,0.94)\$	0.94(0.84,1.05)	1.13(1.07,1.19)*
Oral EE+P - Low Dose	0.91(0.84, 0.99)	0.86(0.76, 0.98)	1.00(0.88,1.14)	0.90(0.77,1.04)	0.88(0.75,1.03)	0.73(0.53,1.00)	0.95(0.81,1.10)
Oral EE+P - Medium Dose	0.95(0.89,1.01)	0.88(0.80, 0.97)	0.95(0.86,1.05)	0.95(0.85,1.06)	0.94(0.84,1.06)	1.03(0.84,1.27)	1.13(1.02,1.26)
Transdermal E2+P - Medium Dose	1.03(1.00,1.07)	0.91(0.85, 0.97)	0.96(0.90,1.02)	0.93(0.87,1.00)	0.98(0.91,1.05)	0.90(0.77,1.05)	1.01(0.94,1.09)
Progestin monotherapy	1.03(1.01,1.05)↑	1.04(1.01,1.07)	1.03(1.00,1.06)	0.99(0.95,1.02)	1.04(1.01,1.08)	0.86(0.81,0.93)\$	0.99(0.95,1.03)

Notes: Data are presented as adjusted Hazard Ratio (aHR) and its 95% Confidence Interval (CI).

Abbreviations: IHD = ischemic heart diseases; HF = heart failure; VTE = venous thromboembolism; AFB = atrial fibrillation; AMI = acute myocardial infarction.

 $[\]uparrow$ = very significantly high with P-value < 0.001, \uparrow = significantly high with 0.001 ≤ P-value < 0.05

 $^{$\}downarrow$= very significantly low with P-value < 0.001, \downarrow= significantly low with <math>0.001 \le P$ -value < 0.05

The risk of all-cause mortality associated with HT use

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

On average, ET use was associated with a significant, 20% reduction in mortality risk relative to no ET use (Table 4-a) which translated to 77,401 fewer expected deaths in our large population. All combinations of ET type, route, and dose were also associated with reduced mortality risk. The marginal risk of E2 on mortality was significantly less than that of CEE. Vaginal, transdermal, and oral preparation, in order by size of mortality risk, each had significantly less mortality risk than the one after. The mortality risk of low and medium doses were significantly less than high dose but were not different from each other. Overall, EPT was associated with significant 12% reduction in marginal risk of mortality. Progestin monotherapy had no significant association. Interestingly, oral CEE medium dose, comparable to the drug in the WHI trial of ET, exhibited less risk reduction in mortality (9%) than overall ET (Table 6-a). The 6,405,685 patients (90% of those in the primary analysis) still in the study 12 months after Part D enrollment were the subjects for our ITT analysis. No censoring occurred after the 12month cut-off in the ITT analysis; so, could not have shaped these results. Yet, marginal association between each type, route and dose level of HT and death from this analysis paralleled and exceeded the mortality reduction observed in the primary analysis (Table 3-b). So, the biases due to informative censoring are unlikely to account for the mortality reduction observed in the primary analysis.

The risk of breast, lung, endometrial, colorectal, and ovarian, cancer associated with HT use

During our study period, breast cancer incidence was four times that of any other study cancer

(Table 3). ET use was associated with significant reduction in marginal risk of breast cancer, 18% overall, as well as within each combination of ET type, route, and dose size (Table 4-c). Oral ET

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

Effects of Hormone Therapy on survival, cancer, cardiovascular, and dementia risks

exhibited significantly greater reductions than transdermal and transdermal ET significantly greater than vaginal. Furthermore, CEE was associated with significantly greater risk reduction for breast cancer than E2 - a pattern opposite to what we saw with mortality as the outcome. The intervention in WHI's 13-year long-term follow-up postintervention study, oral CEE 0.625 mg, was associated with a 21% % risk reduction for breast cancer (5). Seventy percent of our oral CEE medium dose prescriptions were 0.625 mg, same strength as the WHI dose, 11% were greater (0.9 mg) and 19% less (0.45 mg) than 0.625 mg. In our study, oral CEE medium dose use was associated with a 29% risk reduction and was the second best among all oral ET (Table 6-c). To the negative, both EPT and progestin monotherapy significantly *increased* the risk of breast cancer (Table 3-c). ET was associated with 13% and 14% decrease in the risks of lung and colorectal cancers, respectively. EPT also exhibited reductions in lung and colorectal cancer risks but by smaller amounts than ET. Progestin monotherapy was also associated with reduced lung cancer risk but had no association with colorectal cancer risk (Table 3-d & f). With ET use, endometrial, and ovarian cancer risks declined moderately (Table 3-e & g) but this finding is likely an artifact of the selective use of ET in hysterectomized women who lack the organs where such cancers could arise. More than half of hysterectomized women also had bilateral oophorectomy (28). So, these two findings might not be meaningful. On the other hand, 35% risk reduction of endometrial cancer associated with EPT use could be meaningful because it is usually prescribed for women with an intact uterus.

The risk of IHD, CHF, VTE, Stroke, AFM, AMI, and Dementia, risk associated with HT

IHD occurred in more than a million subjects, twice the size of the next most frequent CV condition, CHF. So, ET's 3% increased risk of IHD is of overweight importance. Most types, routes and dose levels of ET were also associated with increased risk of IHD, up to 19% with the injectables, but less so (3-4%) in other types, route, and doses. Specifically, low dose oral CEE and E2 were associated with significant risk reduction for IHD by 3% and 2%, respectively (Table 7-a). Progestin monotherapy had the same 3% increased risk for IHD as ET. Interestingly, EPT formulations, overall, were associated with a significant 4% risk reduction of IHD (Table 4a). To the positive, ET use, overall, was associated with 5% decrease in the risk of CHF (Table 4-b). However, among the ET subgroups of high dose and injectable ET were associated with increased risk of CHF. As was true for IHD, all EPT formulations were associated with reduced CHF risk. Overall ET use had small or no, associations with, stroke or dementia, risk (Table 4-d & g). However, high and medium doses of oral E2 and CEE had important increased risk of stroke, reaching 25% with high dose oral CEE (Table 7-d & g). Both estrogen types (CEE and E2) were also associated with increased dementia risk but only with high dose oral preparations. Transdermal and vaginal preparations of ET, that avoid first pass travel through the liver were associated with small reduced or null risk of both conditions, consistent with the results of other studies (29) and with the procoagulant and proinflammation effects of estrogen's liver passage (30,31). EPT use, on average, was also associated with small but significant, increased risk of dementia and, decreased risk of all 6 CV conditions.

Discussion

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

This study is a population-based retrospective observational study that explored the associations between estrogen types, routes, and dose size and all-cause mortality, dementia, 5 common cancers, and 6 cardiovascular, conditions using an extended Cox regression analysis. Important limitations included that data availability only began at age 65; hysterectomy information was unavailable for most of our subjects.; we depended on claims for encounter diagnoses and could not validate them through chart review; and, as is true for all observational studies, differential influences of unmeasured confounders, such as adherence to healthy behavior among HT users, could have been present.

One strength was the use of filled prescription records, rather than patient recall, to ascertain HT use. Another strength was its size —a study population of more than 7 million menopausal women, nearly an order of magnitude larger than any previous HT study (32). Its large size let us estimate differences in associations between each of 22 HT drug type, route and dose combinations on the one hand and the many study outcomes on the other.

Association with all-cause mortality

ET use, overall, was associated with a 20% reduction in mortality risk considering all ET preparations together. The sole estrogen preparation studied in the WHI trials was 0.625 mg of oral CEE, and it exhibited a close to significant, 6% (HR=0.94; 95% CI 0.88-1.01) mortality reduction in the 18-year long-term follow-up of the WHI trails (33). This result gives some plausibility to the 9% mortality reduction we observed in association with the use of our medium dose, oral CEE which was almost identical to the drug randomized in WHI's estrogen only trial. In our study, vaginal E2 in low and medium doses were associated with greatest reduction of mortality risk (29-40%) (Table 6-a). Our overall mortality results are consistent with the mortality results from an meta-analysis of 31 observational and RCT studies that reported reduced mortality among HT users (34) and with the re-analyses of the Prostate, Lung, Colorectal, and

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

Effects of Hormone Therapy on survival, cancer, cardiovascular, and dementia risks

Ovarian (PLCO) Cancer Screening RTC, which reported a 23% decrease in all-cause mortality among current users of any HT (35). Associations with cancer In our study, overall ET use and oral CEE medium dose use were associated with an 18% and 29% reduction of breast cancer risk, respectively. The long-term follow-up of the WHI study reported a significant, and similarly sized, 21% reduction in breast cancer incidence (36) giving credence to this result. In our study, ET use was also associated with significantly reduced colorectal (14%) and lung (13%) cancer risk as was EPT, but to a lesser degree. A few observational studies support our observations of reduced lung cancer rates in association with HT use (37,38), though there is controversy. Two observational studies (39,40) and a re-analysis of the PLCO trial data (35) support our protective associations between HT use and colorectal cancer. The greater incidence of colorectal (+79%) (41) and lung cancer (+26%) (42) among patients with lower level of estrogen due to oophorectomy as part of their hysterectomy compared to hysterectomized patients without ovary removal also support our results by implying that estrogen protects against these two cancers. On the downside, both EPT and progestin alone were associated with significant increases (11% and 9% respectively) in breast cancer risk. Associations with CV disease and dementia Our data revealed a 3% increase in risk for IHD with ET use compared to no use. However, this increased risk is concentrated in the use of high (9%) and medium (2%) dose levels. Low dose

ET, used by one third of ET users, exhibited a salubrious, 2%, decreased risk for IHD. The associations between ET use and other CV conditions was also to the good—4-11% risk reductions. E2 and vaginal/transdermal compared to CEE and oral preparation exhibited numerically lower risks for all CV conditions. It further suggests that a similar decrease in dementia risk would accrue when low dose, topical (vaginal, transdermal) and E2, were prescribed and in stroke risk when low dose topicals and low dose oral E2 were prescribed. Topical ET preparations in our study, that would avoid the procoagulant and proinflammatory effects ascribed to liver passage (30,31), were associated with *reduced* risk of both conditions, consistent with the results of other studies (29).

Overall considerations

The risk reduction associated with various HT we saw generally favor less use of EPT, more use of the topical (vaginal or transdermal) rather than the oral route, use E2 rather than CEE, and low or medium dose rather than high dose for menopausal care. These advantages have been emphasized by others (43) and our trend data suggest prescribers have adopted them to some degree. However, our results on breast cancer are less consistent with patterns we saw with mortality as the outcome. ET use overall exhibited a decreased risk of breast cancer, but the reduction was significantly greater among CEE, oral route, and high dose, uses, than their counter parts. Further our EPT was used only by small subset of HT users (12%) and in that subset its use was associated with a reduction in the risk of endometrial cancer.

We did not include fractures as an outcome in our study. However, among the outcomes we included, we saw significant association with the use of specific HT medications that paralleled effects seen in each of the *significant* WHI end points including, the decreased incidence of colorectal cancer with both ET and EPT use (35), the decreased incidence of breast cancer with

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

Effects of Hormone Therapy on survival, cancer, cardiovascular, and dementia risks

ET use, the increased incidence of breast cancer with EPT respectively and the decreased incidence of endometrial cancer with EPT use (36). These parallels give credence to our observational results. Our follow-up began when women entered Medicare at about age 65, but it is likely that many of them started taking HT closer to the time of their menopausal symptoms and continued it into their Medicare years. If so, our positive results align with the timing hypotheses (44) that asserts HT use early in menopauses is better than later, but extend it by reporting positive effects with usage continued into Medicare years. Such use is not a rarity per our data. The FDA's black box warning about HT (45) extrapolates from the deleterious effect of EPT on breast cancer (1) and dementia (46) to all forms of ET, because no studies to the contrary existed then. Now, such studies do exist. The long-term WHI studies reported a significant decrease in breast cancer incidence (5) and death due to Alzheimer's disease (33), among patient in the ET study arm. Furthermore, many studies suggest that E2, topical routes, and low doses may produce better outcomes than CEE, oral and medium dose (0.625 mg) studied in the WHI's ET study (47,48).Menopausal HT of all types has been maligned by the results of earliest WHI study (1), long public memory of the frightening media reports about it (2) and lack of attention to recent more positive studies. Our study though purely observational raises the possibility of important improvements in survival and reduction in the risk of three cancers. We hope our results stimulate, interest in hormone therapy and further observational studies using other large national database and biologic research, to support them.

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

Effects of Hormone Therapy on survival, cancer, cardiovascular, and dementia risks

Acknowledgement The authors thank Terry Therneau (PhD, Professor of Biostatistics, Mayo Clinic) for his guiding our use of time varying Cox regression to this data set and especially for the idea of using Intention to treat approach to identify biases due to censoring. **Funding Statement** This research was supported in part by the Intramural Research Program of the National Library of Medicine, National Institutes of Health. The authors received no specific funding for this work. **Competing Interests Statement** The authors do not have competing interests. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Library of Medicine, National Institutes of Health. **Contributorship Statement** SHB and CJM conceived and designed the study. SHB and FB performed the statistical analysis. SHB and CJM drafted the manuscript and all authors contributed substantially to the study. **Data Availability Statement** The Medicare claims data belong to CMS, and we do not have permission to publish the raw data. However, the data are available to researchers through the CMS Virtual Research Data Center. We have included almost all study results in our tables and supporting information.

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

Effects of Hormone Therapy on survival, cancer, cardiovascular, and dementia risks

References The Women's Health Initiative Steering Committee. Risks and Benefits of Estrogen Plus Progestin 1. in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial. JAMA J Am Med Assoc. 2002 Jul 17;288(3):321–33. 2. Brown S. Shock, terror and controversy: how the media reacted to the Women's Health Initiative. http://dx.doi.org/103109/136971372012660048 [Internet]. 2012 Jun [cited 2022 Mar 21];15(3):275–80. Available from: https://www.tandfonline.com/doi/abs/10.3109/13697137.2012.660048 3. Langer RD. The evidence base for HRT: what can we believe? Climacteric [Internet]. 2017 Mar 4 [cited 2021 Apr 1];20(2):91–6. Available from: https://www.tandfonline.com/action/journalInformation?journalCode=icmt20 4. The Women's Health Initiative Steering Committee. Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy, JAMA, 2004 Apr 14;291(14):1701. Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, et al. 5. Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women's Health Initiative Randomized Trials. JAMA [Internet]. 2013 Oct 2 [cited 2020 Apr 1];310(13):1353. Available from: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2013.278040 6. The Centers for Medicare & Medicaid Services. CMS Announces New Data Sharing Tool | CMS [Internet]. 2013 [cited 2019 Nov 1]. Available from: https://www.cms.gov/newsroom/pressreleases/cms-announces-new-data-sharing-tool 7. Administration for Community Living. A Profile of Older Americans: 2018. 2018. Cubanski J, Swoope C, Boccuti C, Jacobson G, Casillas G, Griffin S, et al. A Primer on Medicare 8. [Internet]. 2015 [cited 2019 Feb 7]. Available from: http://files.kff.org/attachment/report-a-primer-

on-medicare-key-facts-about-the-medicare-program-and-the-people-it-covers

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

9. Shreibati JB, Manson JAE, Margolis KL, Chlebowski RT, Stefanick ML, Hlatky MA. Impact of hormone therapy on Medicare spending in the Women's Health Initiative randomized clinical trials, Am Heart J [Internet]. 2018 Apr 1 [cited 2020 Oct 28]:198:108–14. Available from: /pmc/articles/PMC5901884/?report=abstract 10. Azzato EM, Greenberg D, Shah M, Blows F, Driver KE, Caporaso NE, et al. Prevalent cases in observational studies of cancer survival: do they bias hazard ratio estimates? Br J Cancer. 2009 Jun 2;100(11):1806–11. 11. Shintani AK, Girard TD, Eden SK, Arbogast PG, Moons KGM, Ely EW. Immortal time bias in critical care research: application of time-varying Cox regression for observational cohort studies. Crit Care Med. 2009 Nov;37(11):2939–45. 12. Husain H, Thamrin SA, Tahir S, Mukhlisin A, Apriani M. The Application of Extended Cox Proportional Hazard Method for Estimating Survival Time of Breast Cancer. IOP Conf Ser J Phys Conf Ser. 2018;979:12087. 13. NATIONAL LIBRARY OF MEDICINE. DailyMed [Internet]. DailyMed. [cited 2020 Oct 29]. Available from: https://dailymed.nlm.nih.gov/dailymed/ 14. DailyMed - DEPO-ESTRADIOL- estradiol cypionate injection [Internet]. [cited 2021 Mar 24]. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9a4229fd-fecd-4ac1-9c4f-6d442533457f 15. DailyMed - DELESTROGEN- estradiol valerate injection [Internet]. [cited 2021 Mar 24]. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8f94df9-0692-4462a7f0-fe019a0a3f07 16. The Chronic Condition Warehouse. Chronic Conditions Data Warehouse: CCW Chronic Condition Algorithms [Internet]. [cited 2017 Jan 23]. Available from: https://www.ccwdata.org/web/guest/condition-categories Baik SH, Fung K-W, McDonald CJ. The mortality risk of Proton Pump Inhibitors in 1.9 Million 17. US Seniors: an extended Cox survival analysis. Clin Gastroenterol Hepatol. 2021 Jan 13;

519 18. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. 520 Stat Med. 2007 May 20;26(11):2389–430. 521 19. Rosenbaum PR, Rubin DB. The Central Role of the Propensity Score in Observational Studies for 522 Causal Effects. Biometrika. 1983;70(1):41–55. 20. 523 Willems SJW, Schat A, van Noorden MS, Fiocco M. Correcting for dependent censoring in 524 routine outcome monitoring data by applying the inverse probability censoring weighted 525 estimator. Stat Methods Med Res [Internet]. 2018 Feb 1 [cited 2022 Jan 25];27(2):323–35. 526 Available from: https://pubmed.ncbi.nlm.nih.gov/26988930/ 527 21. Wyss R, Gagne JJ, Zhao Y, Zhou EH, Major JM, Wang S V., et al. Use of Time-Dependent 528 Propensity Scores to Adjust Hazard Ratio Estimates in Cohort Studies with Differential Depletion 529 of Susceptibles. Epidemiology [Internet]. 2020 Jan 1 [cited 2022 Jan 27];31(1):82–9. Available 530 from: https://journals.lww.com/epidem/Fulltext/2020/01000/Use of Time Dependent Propensity Scor 531 532 es_to_Adjust.9.aspx Spreeuwenberg MD, Bartak A, Croon MA, Hagenaars JA, Busschbach JJV, Andrea H, et al. The 533 22. 534 multiple propensity score as control for bias in the comparison of more than two treatment arms: An introduction from a case study in mental health. Med Care [Internet]. 2010 Feb [cited 2022 Feb 535 536 7];48(2):166–74. Available from: https://journals.lww.com/lww-537 medicalcare/Fulltext/2010/02000/The_Multiple_Propensity_Score_as_Control_for_Bias.12.aspx 538 23. Adams H, Adams HHH, Jackson C, Rincon-Torroella J, Jallo GI, Quiñones-Hinojosa A. 539 Evaluating extent of resection in pediatric glioblastoma: a multiple propensity score-adjusted 540 population-based analysis. Child's Nerv Syst [Internet]. 2016 Mar 1 [cited 2022 Feb 7];32(3):493– 541 503. Available from: https://link.springer.com/article/10.1007/s00381-015-3006-x 542 24. Ranganathan P, Pramesh CS. Censoring in survival analysis: Potential for bias. Perspect Clin Res 543 [Internet]. 2012 [cited 2022 Mar 8];3(1):40. Available from: /pmc/articles/PMC3275994/ 544 25. Olijnyk L, Darsaut TE, Öhman J, Raymond J. Understanding intent to treat analyses: An important

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

Effects of Hormone Therapy on survival, cancer, cardiovascular, and dementia risks

lesson from the international cooperative study on the timing of aneurysm surgery. Neurochirurgie [Internet]. 2022 Feb [cited 2022 Mar 23]; Available from: https://pubmed.ncbi.nlm.nih.gov/35143810/ 26. McCoy CE. Understanding the Intention-to-treat Principle in Randomized Controlled Trials. West J Emerg Med [Internet]. 2017 Oct 1 [cited 2022 Mar 7];18(6):1075. Available from: /pmc/articles/PMC5654877/ 27. Samson LW, Finegold K, Ahmed A, Jensen M, Filice CE, Joynt KE. Examining Measures of Income and Poverty in Medicare Administrative Data. Med Care [Internet]. 2017 Dec [cited 2021] Mar 23];55(12):e158–63. Available from: https://journals.lww.com/00005650-201712000-00024 28. Parker WH. Bilateral Oophorectomy versus Ovarian Conservation: Effects on Long-term Women's Health. J Minim Invasive Gynecol. 2010 Mar 1;17(2):161–6. 29. Mohammed K, Dabrh AMA, Benkhadra K, Al Nofal A, Carranza Leon BG, Prokop LJ, et al. Oral vs transdermal estrogen therapy and vascular events: A systematic review and meta-analysis. J Clin Endocrinol Metab [Internet]. 2015 Nov 1 [cited 2022 Mar 29];100(11):4012–20. Available from: https://academic.oup.com/jcem/article/100/11/4012/2836071 30. Vehkavaara S, Silveira A, Hakala-Ala-Pietilä T, Virkamäki A, Hovatta O, Hamsten A, et al. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost [Internet]. 2001 Dec 8 [cited 2022 Mar 28];85(4):619–25. Available from: http://www.thieme-connect.com/products/ejournals/html/10.1055/s-0037-1615643 Luyer MDP, Khosla S, Owen WG, Miller VM. Prospective Randomized Study of Effects of 31. Unopposed Estrogen Replacement Therapy on Markers of Coagulation and Inflammation in Postmenopausal Women. J Clin Endocrinol Metab [Internet]. 2001 Aug 1 [cited 2022 Mar 28];86(8):3629–34. Available from: https://academic.oup.com/jcem/article/86/8/3629/2848792 32. Banks E, Beral V, Bull D, Reeves G, Austoker J, English R, et al. Breast cancer and hormonereplacement therapy in the Million Women Study, Lancet (London, England) [Internet], 2003 Aug

571 9 [cited 2022 Mar 10];362(9382):419–27. Available from: 572 https://pubmed.ncbi.nlm.nih.gov/12927427/ 573 33. Manson JAE, Aragaki AK, Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, et al. 574 Menopausal hormone therapy and long-term all-cause and cause-specific mortality: The Women's 575 Health Initiative randomized trials. JAMA - J Am Med Assoc. 2017 Sep 12;318(10):927–38. 576 34. Stute P, Stadler A, Heufelder A. The impact of menopausal hormone therapy on overall mortality 577 - a comprehensive review. https://doi.org/101080/1369713720201767568 [Internet]. 2020 Sep 2 [cited 2022 Apr 11]:23(5):447–59. Available from: 578 579 https://www.tandfonline.com/doi/abs/10.1080/13697137.2020.1767568 580 35. Symer MM, Wong NZ, Abelson JS, Milsom JW, Yeo HL. Hormone Replacement Therapy and 581 Colorectal Cancer Incidence and Mortality in the Prostate, Lung, Colorectal, and Ovarian Cancer 582 Screening Trial. Clin Colorectal Cancer. 2018 Jun 1;17(2):e281–8. 583 Espeland MA, Shumaker SA, Leng I, Manson JE, Brown CM, LeBlanc ES, et al. Long-Term 36. 584 Effects on Cognitive Function of Postmenopausal Hormone Therapy Prescribed to Women Aged 50 to 55 Years. JAMA Intern Med [Internet]. 2013 Aug 12 [cited 2022 Apr 6];173(15):1429–36. 585 586 Available from: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/1726979 587 37. Schwartz AG, Wenzlaff AS, Prysak GM, Murphy V, Cote ML, Brooks SC, et al. Reproductive 588 factors, hormone use, estrogen receptor expression and risk of non-small-cell lung cancer in 589 women. J Clin Oncol. 2007 Dec 20;25(36):5785-92. 590 38. Pesatori AC, Carugno M, Consonni D, Hung RJ, Papadoupolos A, Landi MT, et al. Hormone use 591 and risk for lung cancer: a pooled analysis from the International Lung Cancer Consortium 592 (ILCCO). Br J Cancer 2013 1097 [Internet]. 2013 Sep 3 [cited 2022 Mar 11];109(7):1954–64. 593 Available from: https://www.nature.com/articles/bjc2013506 594 39. Newcomb PA, Zheng Y, Chia VM, Morimoto LM, Doria-Rose VP, Templeton A, et al. Estrogen 595 Plus Progestin Use, Microsatellite Instability, and the Risk of Colorectal Cancer in Women. 596 Cancer Res [Internet]. 2007 Aug 1 [cited 2022 Mar 29]:67(15):7534–9. Available from:

597 https://aacrjournals.org/cancerres/article/67/15/7534/533438/Estrogen-Plus-Progestin-Use-598 Microsatellite 599 40. Delellis Henderson K, Duan L, Sullivan-Halley J, Ma H, Clarke CA, Neuhausen SL, et al. 600 Menopausal hormone therapy use and risk of invasive colon cancer: the California Teachers 601 Study. Am J Epidemiol [Internet]. 2010 Feb [cited 2022 Mar 9];171(4):415–25. Available from: 602 https://pubmed.ncbi.nlm.nih.gov/20067917/ 603 41. Koch T, Therming Jørgensen J, Christensen J, Duun-Henriksen AK, Priskorn L, Kildevæld Simonsen M, et al. Bilateral oophorectomy and rate of colorectal cancer: A prospective cohort 604 605 study. Int J Cancer [Internet]. 2022 Jan 1 [cited 2022 Mar 11];150(1):38–46. Available from: 606 https://onlinelibrary.wiley.com/doi/full/10.1002/ijc.33776 607 42. Parker WH. Ovarian conservation versus bilateral oophorectomy at the time of hysterectomy for 608 benign disease. Menopause [Internet]. 2014 Feb [cited 2022 Mar 11];21(2):192-4. Available from: 609 https://journals.lww.com/menopausejournal/Fulltext/2014/02000/Ovarian conservation versus bi 610 lateral_oophorectomy.16.aspx 611 Speth RC, D'ambra M, Ji H, Sandberg K. A heartfelt message, estrogen replacement therapy: use 43. 612 it or lose it. Am J Physiol Heart Circ Physiol [Internet]. 2018 Dec 1 [cited 2022 Apr 613 6];315(6):H1765–78. Available from: https://pubmed.ncbi.nlm.nih.gov/30216118/ 614 44. Hodis HN, Collins P, Mack WJ, Schierbeck LL. The timing hypothesis for coronary heart disease 615 prevention with hormone therapy: past, present and future in perspective. Climacteric [Internet]. 616 2012 Jun 22 [cited 2021 Apr 9];15(3):217–28. Available from: 617 http://www.tandfonline.com/doi/full/10.3109/13697137.2012.656401 618 45. U.S. Food and Drug Administration. Estrace Tablets. 619 Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, et al. Estrogen Plus 46. Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal 620 Women - The Women's Health Initiative Memory Study: A Randomized Controlled Trial. J Am 621 622 Med Assoc [Internet]. 2003 May 28 [cited 2021 Mar 24];289(20):2651–62. Available from:


www.jama.com Yaffe K, Vittinghoff E, Ensrud KE, Johnson KC, Diem S, Hanes V, et al. Effects of Ultra-Low-47. Dose Transdermal Estradiol on Cognition and Health-Related Quality of Life. Arch Neurol [Internet]. 2006 Jul 1 [cited 2022 Apr 11];63(7):945–50. Available from: https://jamanetwork.com/journals/jamaneurology/fullarticle/791814 48. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. Estrogen therapy and risk of cognitive decline: Results from the Women's Estrogen for Stroke Trial (WEST). Am J Obstet Gynecol. 2005 Feb 1;192(2):387–93.

Description of S1 Table
S1 Table. All menopausal hormone therapy estrogen and progestin drugs available in Medicare prescription drug claims data during our 13-year study.

S2 Table. List of CPT AND ICD Diagnosis and Procedure codes used to define the absence of a uterus or hysterectomy surgery.

Figure 1. Trend in the use of Hormone Therapy (HT) by type and route

(a) Secular Trend in HT use by type



(b) Secular Trend in HT use by route

